A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
一项针对 II/III 期三阴性乳腺癌 (TNBC) 患者进行顺铂、紫杉醇联合或不联合依维莫司治疗的随机 II 期新辅助治疗研究:治疗反应和长期结果与 DNA 损伤反应基因突变频率增加、TNBC 亚型、AR 状态和 Ki67 相关
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-16-3055
Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, Vandana G Abramson, Aditya Bardia, Melinda E Sanders, M Gabriela Kuba, Monica V Estrada, J Scott Beeler, Timothy M Shaver, Kimberly C Johnson, Violeta Sanchez, Jennifer M Rosenbluth, Patrick M Dillon, Andres Forero-Torres, Jenny C Chang, Ingrid M Mesz